Encouraging prospects for immunisation against primary cytomegalovirus infection

Vaccine

Volumn 19, Issue 11-12, 2001, Pages 1356-1362

  Griffiths, P D ^a   McLean, A ^b   Emery, V C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Modelling; Neonate; R0

Indexed keywords

CYTOMEGALOVIRUS VACCINE; RUBELLA VACCINE;

AGE; ARTICLE; CONGENITAL INFECTION; CONGENITAL RUBELLA SYNDROME; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION SENSITIVITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; SEROPREVALENCE;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INFANT, NEWBORN; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; VIRAL VACCINES;

EID: 0035825103     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00377-7     Document Type: Article

References (30)

1. Cytomegalovirus
2. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
3. A prospective study of primary cytomegalovirus infection during pregnancy: Final report
4. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome
5. Increased rate of cytomegalovirus infection among parents of children attending day-care centers
6. Increased rate of cytomegalovirus infection among day care center workers
7. Congenital cytomegalovirus disease - 20 years is long enough
8. Improved prenatal diagnosis of congenital human cytomegalovirus infection by a modified nested polymerase chain reaction
9. Prenatal diagnosis of congenital cytomegalovirus infection: Light and shade
10. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus
11. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response
12. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes
13. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
14. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
15. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB
16. Preclinical evaluation of an ALVAC (canarypox) - Human cytomegalovirus glycoprotein B vaccine candidate
17. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)
18. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
19. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization
20. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
21. Mathematical modelling of the immunisation of populations
22. Current status of rubella in the United States, 1969-1975
23. Strategy for rubella vaccination
24. Increase in congenital rubella occurrence after immunisation in Greece: Retrospective survey and systematic review
25. Congenital and maternal cytomegalovirus infections in a London population
26. Immunisation strategies for viral diseases in developing countries
27. Working parents: The impact of day care and breast-feeding on cytomegalovirus infections in offspring
28. Current prospects for immunization against cytomegaloviral disease